The prespecified secondary outcome of hyperkalemia leading to discontinuation was not observed in the placebo and finerenone 10-mg/d groups ; incidences in the finerenone 7.5 - , 15 - , and 20-mg/d groups were 2.1 % , 3.2 % , and 1.7 % , respectively .